Clinical application of Bailing tablet in chronic obstructive pulmonary disease

Clinical application of Bailing tablet in the treatment of chronic obstructive pulmonary disease in post-epidemic era

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100050118

Enrollment

Unknown

Registered

2021-08-16

Start date

2021-09-01

Completion date

Unknown

Last updated

2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease (COPD)

Interventions

Non-smoking group A:Indacaterol/Gronium bromide

Non-smoking group B:Indacaterol/Gronium bromide +Bailing tablet

Smoking group A:Indacaterol/Gronium bromide

Smoking group B:Indacaterol/Gronium bromide +Bailing tablet

Eligibility

Sex/Gender

All

Age

45 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for chronic obstructive pulmonary disease, and TCM syndrome differentiation belongs to the lung and kidney deficiency type; 2. Aged 45-80 years; 3. Voluntarily participate in clinical research and sign the informed consent; 4. Outpatients.

Exclusion criteria

Exclusion criteria: 1. Combined with more serious primary diseases such as heart, kidney, liver, brain, hematopoietic system; 2. Pregnant or lactating patients; 3. Those who cannot cooperate and have severe cognitive impairment; 4. History of glucocorticoid or p-receptor agonist use within the past 1 month; 5. Patients with contraindications to the study drug.

Design outcomes

Primary

Measure	Time frame
TCM syndrome integral;Lung function;	—

Secondary

Measure	Time frame
St. George's respiratory questionnaire;	—

Countries

China

Contacts

Public ContactCheng Yixing

Huzhou Hospital of Traditional Chinese Medicine

17593842@qq.com+86 13567220583

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026